Get the Stockscreener App
452.21
0.95%
4.26
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $452.21, with a volume of 555.48K.
It is up +0.95% in the last 24 hours and up +8.15% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$447.95
Open:
$441.03
24h Volume:
555.48K
Relative Volume:
0.21
Market Cap:
$244.48B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
31.45
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+3.16%
1M Performance:
+8.15%
6M Performance:
+33.17%
1Y Performance:
+54.82%
1-Day Range:
$439.57
$454.66
1-Week Range:
$437.19
$450.98
52-Week Range:
$288.00
$454.66
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
452.21 | 244.48B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,292.96 | 1.15T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.62 | 653.89B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
287.82 | 508.61B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.78 | 349.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.81 | 296.16B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-26 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-05-26 | Reiterated | BMO Capital Markets | Outperform |
| Aug-05-26 | Reiterated | BofA Securities | Underperform |
| Aug-05-26 | Reiterated | Canaccord Genuity | Hold |
| Aug-05-26 | Reiterated | Morgan Stanley | Equal-Weight |
| Aug-05-26 | Reiterated | Oppenheimer | Outperform |
| Aug-05-26 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-05-26 | Reiterated | Robert W. Baird | Underperform |
| Aug-05-26 | Reiterated | Truist | Hold |
| Aug-05-26 | Reiterated | Wells Fargo | Equal Weight |
| May-05-26 | Downgrade | Erste Group | Buy → Hold |
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
FDA warns Amgen over cancer drug promotional video - TradingView
Amgen Announces the Appointment of David Gibbs to Its Board of Directors - Oncodaily
Amgen (AMGN) Maintains Quarterly Dividend at $2.52 with 2.25% Yi - GuruFocus
AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND - Amgen
Regeneron, Amgen Further Narrow Lawsuit Over Eylea Biosimilars - Bloomberg Law News
FDA Flags Amgen's Vectibix Promotional Video as Misleading, Rais - GuruFocus
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 - Amgen
Beyond the DNA We Inherit: A Broader View of Human Genetics - Amgen
Amgen receives FDA warning letter over Vectibix ad - Seeking Alpha
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - Yahoo Finance
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool
FDA warns Amgen over cancer drug promotional video - Reuters
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Amgen Stock: A Biotech Bargain Heading Into Q3 Earnings (NASDAQ:AMGN) - Seeking Alpha
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS - Amgen
FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data - BioPharma Dive
FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool
Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer - Benzinga
Amgen's cancer drug combo cut death risk by 58% in lung cancer trial - Quartz
Is AMGN Overvalued? DCF Says Worth $204 - GuruFocus
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Amgen Inc. $AMGN Stock Position Raised by Sigma Planning Corp - MarketBeat
2,418 Shares of Amgen Inc. $AMGN Bought by IRON Financial LLC - MarketBeat
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study - Bloomberg.com
Oppenheimer reiterates Amgen stock rating on cancer drug data - Investing.com
Amgen Inc (Derivatives) Price History and Historical Data - CoinMarketCap
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual CongressSlideshow - Seeking Alpha
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER - Amgen
Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer - Bloomberg.com
Here's Why Amgen (AMGN) Fell More Than Broader Market - Zacks Investment Research
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Innovation Lives Here: 25 Years of Amgen in Cambridge - Amgen
Amgen Inc. Estimates – NASDAQ:AMGN - TradingView
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) interactive stock chart - Yahoo Finance UK
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) latest stock news and headlines - Yahoo Finance UK
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Amgen (AMGN) Gains As Market Dips: What You Should Know - Yahoo Finance
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Amgen stock hits all-time high at 447.09 USD By Investing.com - Investing.com Canada
Amgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a Year - CSRwire
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
| Khosla Rachna | Officer |
Aug 13 '26 |
Proposed Sale |
412.76 |
1,252 |
516,775 |
0 |
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | Officer |
Aug 11 '26 |
Proposed Sale |
414.21 |
2,000 |
828,420 |
0 |
| Derek Miller | Officer |
Aug 06 '26 |
Proposed Sale |
404.85 |
3,890 |
1,574,866 |
0 |
| Grygiel Nancy A. | Officer |
Aug 06 '26 |
Proposed Sale |
447.17 |
2,670 |
1,193,940 |
0 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
0.66%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):